Description: Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.
Home Page: genetype.com
GTG Technical Analysis
60-66 Hanover Street
Fitzroy,
VIC
3065
Australia
Phone:
61 3 8412 7000
Officers
| Name | Title |
|---|---|
| Mr. Simon Morriss | Chief Exec. Officer |
| Dr. Richard Allman Ph.D. | Chief Scientific Officer |
| Mr. Carl S. Stubbings BSc | Chief Commercial Officer |
| Mr. Tony Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D. | CFO & Company Sec. |
| Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA | Consultant |
| Mr. Kevin Camilleri | Chief Exec. Officer of EasyDNA |
Exchange: AU
Country: AU : Australia
Currency: Australian Dollar (A$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6859 |
| Price-to-Sales TTM: | 2.0034 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 52 |